Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS)
description
Transcript of Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS)
Tuberculosis-associated immune reconstitution inflammatory syndrome
(TB-IRIS)
Graeme MeintjesUniversity of Cape Town
Imperial College London
Webinar25 Nov 2013
ART
Viral suppression
(CD4 rise)
Restoration of pathogen-specific immunity
Regression or prevention of opportunistic infections
Inflammatory reactions days tomonths after starting ART = IRIS
+ -
IRIS = Immune Reconstitution Inflammatory SyndromeIRD = Immune Restoration Disease
Wide range of IRIS conditions described• Mycobacteria
– TB– MAC– Leprosy– BCG– Other NTM
• Fungi– Cryptococcus– Histoplasmosis– PCP– Dermatophytes– Candida– Aspergillus– Penicillium
• Viruses– Hepatitis B and C– HSV 1 and 2– HZV– CMV– JC virus– BK virus– Molluscum– Warts– Parvovirus B19– HIV dementia
• Protozoans– Toxoplasmosis– Leishmaniasis– Microsporidia– Cryptosporidia
• Helminths– Schistosoma– Strongyloides
• Bacteria– Bartonella
• Other skin conditions– Acne and folliculitis
• Auto-immune and inflammatory conditions– Guillain-Barre syndrome– Sarcoidosis– Grave’s– Peyronie’s– Rheumatological conditions (SLE, RA, Reiter’s)– Tattoo pigment and foreign body reactions– Cerebral vasculitis– TTP– LIP
• Tumours– Kaposi’s sarcoma, lymphoma
Patients on TB treatment
Patients not onTB treatment
ParadoxicalTB-IRIS
ART
ART-associated TBART
Unmasking TB-IRIS
OVERVIEW
• Clinical presentations– Neurological TB-IRIS– Hepatic TB-IRIS– Prolonged TB-IRIS
• Diagnosis• Corticosteroids for treatment• ART timing• Prevention trial
What is the typical time of onset of paradoxical TB-IRIS after ART start?
1. 3-10 days2. 1-4 weeks3. 4-8 weeks4. Around 3 months
Patient diagnosed with TB and started on TB treatment
Improving on TB treatment then starts ART
Recurrence of TB symptoms and new or recurrent clinical manifestations of TB
(Usually 1-4 weeks after starting ART)
Paradoxical TB-IRIS
Paradoxical TB-IRIS characteristics• Incidence 8 – 54% (15.7% in meta-analysis)• Onset of symptoms: Median 14 days from ART start• Focal and systemic inflammatory features
– Fever, tachycardia, weight loss• Hospitalisation in up to 48%• Median duration 2-3 months• Mortality infrequent
– Meta-analysis 3.2% (substantially higher if CNS IRIS)
Meintjes Lancet Infect Dis 2008;8:516, Muller Lancet Infect Dis 2010;10:251, Agarwal AIDS Res Ther 2012;9:17,Meintjes Clin Infect Dis 2009;48:667, Burman IJTLD 2007;11:1282
Worsening pulmonary infiltrate and cavitation due to TB-IRIS
Massive psoas abscess
Pericardial tamponade due to paradoxical TB-IRIS
On TB treatment prior to ART 3 weeks on ART(1 litre drained at pericardiocentesis)
Neurological TB-IRIS
• 12% with paradoxical TB-IRIS have CNS involvement• Up to 47% of TBM patients starting ART develop IRIS• Features
– Meningitis– Tuberculoma/s – Radiculomyelopathy
• Occurs in patients with or without CNS TB prior to ART• Outcomes
– 13% mortality and 18% loss to follow-up in one series– 25% and 75% mortality in other series– Neurological disability
Pepper et al, Clin Infect Dis 2009Marais et al, Clin Infect Dis 2012Agarwal et al, AIDS Res Ther 2012
TBM diagnosis TBM-IRIS
Slide courtesy Suzaan Marais
TBM-IRIS with expressive aphasia
Slide courtesy Suzaan Marais
TBM and PTB prior to ARTTB-IRIS with enlarging mass lesion/cerebral oedema
Patient died
CSF Neutrophils and TBM-IRIS
TBM diagnosisDay 0
ART StartDay 14
2 weeks post ART/IRISDay 28
Non IRIS
Cel
ls/m
m3
IRIS
p=0.01 p<0.0001
MaraisCID 2012
Hepatic TB-IRIS is characterised by which of the following?
1.Severe jaundice on clinical examination2.Elevation in transaminases more then 10 x upper limit of normal3.Non-tender hepatomegaly4.The most prominent LFT abnormality being elevation of Alk Phos and GGT.
Hepatic TB-IRIS case
• 4 months treatment for drug-sensitive pericardial TB• Clinically improved, then started ART• 3 weeks later presented with fever and hepatomegaly• LFT: Bil 52, CBil 31, Alk Phos 1081, GGT 1468, ALT 82, AST
88• CD4 rise from 64 to 221• Biopsy AFB- and TB culture -
Case courtesy of Mark Sonderup
Hepatic TB-IRIS vs DILI
Hepatic TB-IRIS
•RUQ pain, nausea and vomiting•Tender hepatomegaly•Cholestatic LFT derangement•+/- mild jaundice•Usually other TB-IRIS
manifestations
Drug-induced liver injury
•Similar symptoms•Typically not hepatomegaly•Transaminitis +/- jaundice•Absence of other TB-IRIS features
Patients may present with clinical picture between these two
- Biopsy or treat as DILI
Two conditions may co-exist
Prolonged TB-IRIS
• Typically suppurative lymphadenitis & abscesses• Systemically well
• Tuberculomas & cerebral abscesses
• TB-IRIS duration (n = 176)– Median: 70 days– IQR: 41-111 days– IRIS > 90 days: 36%
Bana, unpublished
Prolonged TB-IRIS: Management
• Often repeated aspirations required• Avoid surgical drainage• Repeat TB culture and susceptibility testing• Corticosteroids for > 4 months questionable
unless CNS involved• Experimental therapies
– Thalidomide and TNF-α blockers
• Consider prolonging TB treatment– How adequate is drug penetration?
Key points in TB-IRIS diagnosis
1. Diagnosis of TB confirmed or very likely?
2. Improvement on TB treatment prior to ART?
3. Symptom onset typically 1-4 weeks on ART
4. Deterioration with inflammatory features of TB
5. Consider and exclude differential diagnoses
6. Exclude drug-resistant TB
There is no confirmatory diagnostic test
100 TB-IRIS suspectsscreened usingcase definition
KEY FINDING
Undiagnosed rifampicin resistance in 10.1% of patients (95% CI 3.9-16.4%) presenting with TB-IRIS, after exclusion of known rifampicin resistance and alternative opportunistic diseases
Meintjes Clin Infect Dis 2009;48:667
Lymph node enlargement
Differential diagnoses
• Lymphoma• Kaposi’s • Castleman’s disease
Consider malignancy particularly when LN remains firm
• NTM IRIS• Cryptococcal IRIS
Other important differential diagnosesManifestation Differential diagnoses
Pulmonary infiltrate Bacterial pneumoniaPCPKaposi’s sarcoma
Pleural effusion Bacterial empyemaKaposi’s sarcoma
Meningitis BacterialCryptococcal
Space-occupying lesion ToxoplasmosisCryptococcomaPrimary CNS lymphoma
Fever with general deterioration Bacterial sepsisNTMKaposi’s or lymphoma
*Consider and investigate for DR-TB in all scenarios
Pathogenesis of paradoxical IRIS
Inflammatory reactions directed to antigens of opportunistic infection
Recovery of pathogen-specific immune responses and T-cell activation
Pro-inflammatory cytokines and chemokines
Defective immuneregulatory function
Recovery of innate immunefunction
Prednisone for TB-IRIS: which statement is correct?
1. Prednisone has been shown to reduce the risk of death from TB-IRIS
2. Prednisone should be prescribed to prevent TB-IRIS in high risk patients
3. When prednisone is used to treat TB-IRIS it has been shown to have modest benefits in terms of reducing symptoms and duration of hospitalisation
4. It should not be used because of its side effects in HIV positive patients
• Rationale for steroid trial– Anecdotal reports of symptomatic response– Potential risks in patients with advanced HIV
• 110 participants (55 each arm)• Life-threatening TB-IRIS was an exclusion• Open-label prednisone at physician discretion if clinical
deterioration/relapse
Meintjes et al, AIDS 2010;24:2381
HIV-TB patients recentlystarted ART with
suspected TB-IRIS
Assessed using a clinicalcase definition for TB-IRISand alternative diagnoses
excluded
Inclusion criteriaInformed consent
Randomised
Prednisone1.5mg/kg/day x 2 weeks0.75mg/kg/day x 2 weeks
Identical placebo1.5mg/kg/day x 2 weeks0.75mg/kg/day x 2 weeks
Followed for a total of 12 weeksPrimary endpoint: Total number of days hospitalised + outpatients therapeutic proceduresSecondary endpoints included symptom score, CXR score and steroid side effects
Primary endpointCumulative number of days hospitalized and outpatient
therapeutic procedures (counted as 1 additional day), ITT analysis
Placebo
arm
N = 55
Prednisone
arm
N = 55
P-value
Total days hospitalized 463 282 -
Total number outpatient procedures 28 24 -
Cumulative primary endpoint (median, IQR) 3 (0-9) 0 (0-3) 0.04
Significant reduction in morbidity associated with prednisone treatment
Secondary endpoints
• Consistent benefit, maximal in first 4 weeks, across a range of secondary outcome measures– Symptom score– Karnofsky performance score– MOS-HIV questionnaire (quality of life assessment)– Chest radiology score– C-reactive protein
• 10/55 in prednisone arm relapsed after completing study drug and required re-initiation of prednisone– 4 weeks appeared to be too short for these patients
Adverse events
Placebo
arm
Prednisone
arm
P-value
Death on study 2 (4%) 3 (5%) 0.65
Corticosteroid side effects while on study drug*
3 (5%) 8 (15%) 0.11
Infections while on study drug
17 (31%) 27 (49%) 0.05
Severe infections** 4 (7%) 2 (4%) 0.40
* Included BP > 140/90, oedema, hyperglycaemia, hypomania, acne, Cushingoid features, gastritis symptoms
** WHO stage 4 or invasive bacterial infection
Serum IL-6: Placebo vs Prednisone (week 0, 2 and 4)
Meintjes et al, AJRCCM 2012;186:369
Similar reductions seen in TNFα, IFNγ, IL10, IL12 and CXCL10 on prednisone
Corticosteroids for paradoxical TB-IRIS?
Symptom improvementReduced hospitalisation? Survival benefit in life threatening cases
Potential adverse effects- Kaposi’s- Infections- Metabolic
Diagnostic uncertainty
CASE: 49 year old HIV+ man with CD4=29, diagnosed with drug-susceptible PTB. Started ART 2 weeks after TB treatment. 2 weeks later developed recurrent TB symptoms, worsening of pulmonary infiltrate and new pleural effusion.
MANAGEMENT: Antibiotic, aspiration of pleural effusion, prednisone. TB
cultures of sputum and effusion were negative at TB-IRIS.
Needle aspiration
Major TB-IRIS risk factors
• Low CD4 count
• Short interval between TB treatment and ART
• Disseminated TB
Lawn AIDS 2007;21:335Meintjes Lancet Infect Dis 2008;8:516Burman IJTLD 2007;11:1282
Risk of IRIS
Risk of HIV disease progression
MORTALITY MORTALITY
When to start ART after recent diagnosis of TB?
3 recent large RCTs (SAPIT, STRIDE, CAMELIA)
EarlierART
DeferredART
ART timing and primary endpoints
Death/AIDSp = 0.45 Death/AIDS
p = 0.73
Deathp=0.00638%
ART timing and primary endpoints in patients with CD4 < 50
Deathp=0.00638%
Death/AIDSp=0.0242%
Death/AIDSp=0.0668%
* CAMELIA data represents all patients in trial, majority had CD4 < 50 (median CD4 =25)
SAPiT IRIS incidence(IRIS cases/100 person years)
Naidoo,Annals Intern Med 2012
Implications
• In patients with CD4 < 50: start ART at 2 weeks– Even though more likely to develop IRIS with early ART– Benefit most from early ART in terms of survival and
preventing AIDS events
• In patients with CD4 > 50– ART can be deferred ~ 8 weeks to reduce risk of IRIS– Except patients with severe clinical disease, organ
system dysfunction, low performance score, low BMI or Hb as these are associated with higher mortality
Preventing TB-IRIS in high-risk patients: Randomized placebo-controlled trial of prednisone
(Pred-ART trial)
Graeme Meintjes, Lut Lynen, Robert J Wilkinson, Gary Maartens, Bob Colebunders, Charlotte Schutz, Shaheed Mattee, Funeka Bango, Jan Kuehne, Zuhoor Dadeker, Christiana Noestlinger, Harry van Loen, Joris Menten, Jozefien Buyze, Edwin Wouters, Bill Burman, Raffaella Ravinetto, Friedrich Thienemann, Liz Blumenthal, Cari
Stek, Amanda Jackson, Lorraine Swanepoel, Rene Goliath, Amy Nair
HIV-infectedART-naiveCD4 < 100TB diagnosed
n = 240
Informed consentRandomised 1:1
Start ART+
4 weeks prednisone
Start ART+
4 weeks placebo
Follow-up for 12 weeks(Visits at weeks 1,2,4,8 and 12)
Follow-up for 12 weeks(Visits at weeks 1,2,4,8 and 12)
TB TREATMENT (and CO-TRIMOXAZOLE)TB TREATMENT (and CO-TRIMOXAZOLE)
ARTARTART started within 30 days of TB treatment
Dose of prednisone/placebo: 40mg/day x 2 weeks then 20mg/day x 2 weeksPrimary endpoint: Development of paradoxical TB-IRIS
ClinicalTrials.gov NCT01924286
Paradoxical TB-IRIS only occurs in ART naïve patients starting first line ART.
TRUE or FALSE?
Acknowledgements• Robert Wilkinson• Gary Maartens• Katalin Wilkinson• Suzaan Marais• Charlotte Schutz• Tasnim Bana• Maia Lesosky• Molebogeng Rangaka• Chelsea Morroni• Tolu Oni• Dominique Pepper• Kevin Rebe• Rene Goliath• Helen van der Plas• Marc Mendelson• Priscilla Mouton• Bob Colebunders• Anali Conesa Botella• Raylene Titus• Keira Skolimowska• Kerryn Matthews• Rebecca Tadokera• Mark Sonderup
Pred-ART funders